Skye Bioscience
SKYE
75 hedge funds and large institutions have $39.3M invested in Skye Bioscience in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 10 closing their positions.
300% more call options, than puts
Call options by funds: $84K | Put options by funds: $21K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
3% more funds holding
Funds holding: 73 → 75 (+2)
3.36% less ownership
Funds ownership: 83.09% → 79.73% (-3.4%)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
45% less capital invested
Capital invested by funds: $71.3M → $39.3M (-$32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$531K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$253K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$251K |
| 4 |
LPL Financial
San Diego,
California
|
+$217K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$95.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$708K |
| 2 |
ACM
Altium Capital Management
New York
|
-$639K |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$384K |
| 4 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$250K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$241K |
SKYE Hedge Fund Activity: Q1 2025 in Review
75 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q1 2025, worth a combined $39.3M — down 45% from $71.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SKYE positions and 10 closed out — a net gain of 3 holders — while 17 added to existing stakes and 19 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $531K. The largest seller was Citadel Advisors, exiting entirely with an estimated $708K sold.
- 75 institutional investors held Skye Bioscience (SKYE) as of Q1 2025, up from 73 in Q4 2024.
- Funds reported $39.3M of Skye Bioscience stock for Q1 2025, down 45% quarter-over-quarter.
- 13 funds opened new Skye Bioscience positions in Q1 2025 and 10 closed out, a net change of +3 holders.
- The largest Skye Bioscience buyer in Q1 2025 was Schonfeld Strategic Advisors, an estimated $531K added.
- The largest Skye Bioscience seller in Q1 2025 was Citadel Advisors, an estimated $708K sold.
Based on aggregated 13F filings for Q1 2025.